EP1137646A1 - Derive paroxetinique - Google Patents

Derive paroxetinique

Info

Publication number
EP1137646A1
EP1137646A1 EP99961195A EP99961195A EP1137646A1 EP 1137646 A1 EP1137646 A1 EP 1137646A1 EP 99961195 A EP99961195 A EP 99961195A EP 99961195 A EP99961195 A EP 99961195A EP 1137646 A1 EP1137646 A1 EP 1137646A1
Authority
EP
European Patent Office
Prior art keywords
compound
paroxetine
salt
acid
disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99961195A
Other languages
German (de)
English (en)
Inventor
David Alan c/o SmithKline Beecham Pharma. JONES
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Publication of EP1137646A1 publication Critical patent/EP1137646A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Definitions

  • the present invention relates to a novel compound, to processes for preparing it and to its use in treating medical disorders.
  • the present invention relates to a novel derivative of paroxetine.
  • This invention relates to a novel derivative of paroxetine.
  • the compound of this invention may exist in the free acid form as shown in formula (1) or as the corresponding zwitterion. Both forms are part of this invention.
  • the compound of formula (1) may also exist as salts for example with alkali metals or amines, or addition salts with strong acids. Suitable salts include those with alkali metals, preferably sodium, potassium or lithium, or with a mineral acid, for example hydrochloric acid, or sulphonic acid. Amine salts may include salts with paroxetine itself. Also the compound of formula (1) may exist as a mono- or di-salt, or as a mixed salt.
  • a particularly important salt is the 1 :1 (by mole) salt with paroxetine.
  • Compounds of structure (1) have a chiral centre on the piperidine nitrogen substituent as well as the two chiral centres on the piperidine ring, so may exist in two forms. These forms may be separated by crystallisation or chromatography, optionally in the form of a salt, for example a salt with an optically active base.
  • the present invention also provides a method for the preparation of compounds of formula (1) by the addition reaction of paroxetine (as the free base) to maleic acid.
  • the procedure may be carried out at elevated temperature in an appropriate solvent.
  • solvents suitable for the addition reaction are polar aprotic solvents, for example N.N-dimethylformamide, alcohols such as ethanol and isopropanol, and esters such as ethyl acetate, and hydrocarbons such as toluene.
  • polar aprotic solvents for example N.N-dimethylformamide
  • alcohols such as ethanol and isopropanol
  • esters such as ethyl acetate
  • hydrocarbons such as toluene.
  • the reaction of paroxetine with maleic acid tends to result in the recovery of the paroxetine salt of the compound of formula (1) rather than the free acid. Accordingly the free acid is suitably obtained by preparing the salt and treating the salt to recover the acid.
  • the paroxetine salt of compound (1) may conveniently be prepared by contacting paroxetine free base with maleic acid in a suitable solvent, for example toluene, ethyl acetate or 2-butanol, preferably at elevated temperature, for example above 60°C.
  • a suitable solvent for example toluene, ethyl acetate or 2-butanol, preferably at elevated temperature, for example above 60°C.
  • the paroxetine salt of compound (1) may be isolated by crystallisation, and may be purified by a hot slurry, for example at reflux temperature in an appropriate solvent, for example an ester such as ethyl acetate, an alcohol such as propan-2-ol, or a ketone such as acetone.
  • the paroxetine salt of compound (1) may also be prepared from paroxetine maleate (1 :1) salt by heating in an appropriate solvent, preferably butan-2-ol.
  • Compound (1) may be isolated from its paroxetine salt by acidification with 1 equivalent of acid, for example hydrochloric acid.
  • compound (1) may be prepared by addition of 1 molar equivalent of hydrogen chloride in propan-2-ol to a suspension of the paroxetine salt of compound (1) in propan-2-ol with or without heating, and isolated as the free acid by crystallisation from the reaction medium by the addition of water and acetone.
  • compound (1) free acid may be prepared from the isolated paroxetine salt by treatment with 1 equivalent of hydrochloric acid in acetone followed by crystallisation from the medium.
  • salts of compound (1) for example mono sodium or mono lithium salts may be prepared by reaction of compound (1) with 1 equivalent of base, for example sodium or lithium hydroxide respectively.
  • Another class of salts of compound (1) may be formed by reaction with 2 equivalents of strong base, such as for example the disodium or dipotassium salt.
  • Paroxetine free base may be prepared according to the procedures generally outlined in US Patent No 4,007,196 and EP-B-0 223403. Maleic acid is commercially available.
  • Compound (1) and its salts of this invention are anticipated to be useful to treat and prevent the following disorders:
  • the Disorders are hereinafter referred to as "the Disorders”.
  • the present invention further provides a method for treating and/or preventing any one or more of the Disorders by administering an effective and/or prophylactic amount of a compound of the invention to a sufferer in need thereof.
  • the present invention further provides a pharmaceutical composition for use in the treatment and/or prevention of any one or more of the Disorders which comprises an admixture of a compound of the invention with a pharmaceutically acceptable carrier.
  • the present invention also provides the use of a compound of the invention for treating and/or preventing any one or more of the Disorders.
  • the present invention also provides the use of a compound of the invention in the manufacture of a medicament for treating and/or preventing any one or more of the Disorders.
  • the present invention is applied to the treatment of depression, OCD and panic.
  • compositions containing a compound of this invention may be formulated for administration by any route, and examples are oral, sub-lingual, rectal, topical, parenteral, intravenous or intramuscular administration. Preparations may, if desired, be designed to give slow release of the paroxetine derivative or salt.
  • the medicaments may, for example, be in the form of tablets, capsules, sachets, vials, powders, granules, lozenges, reconstitutable powders, or liquid preparations, for example solutions or suspensions, or suppositories.
  • the composition is usually presented as a unit dose composition containing from 1 to 200mg of active ingredient calculated on a free base basis, more usually from 5 to lOOmg, for example 10 to 50mg such as 10, 12.5, 15, 20, 25, 30 or 40mg by a human patient. Most preferably unit doses contain 20mg of active ingredient calculated on a free base basis. Such a composition is normally taken from 1 to 6 times daily, for example 2, 3 or 4 times daily so that the total amount of active agent administered is within the range 5 to 400mg of active ingredient calculated on a free base basis. Most preferably the unit dose is taken once a day.
  • Preferred unit dosage forms include tablets or capsules.
  • compositions of this invention may be formulated by conventional methods of admixture such as blending, filling and compressing.
  • Suitable carriers for use in this invention include a diluent, a binder, a disintegrant, a colouring agent, a flavouring agent and/or preservative. These agents may be utilised in conventional manner, for example in a manner similar to that already used for marketed anti-depressant agents.
  • compositions include those described EP-B-0223403, and US 4,007,196 in which the products of the present invention may be used as the active ingredients.
  • paroxetine base and maleic acid 0.5 mole equivalents
  • ethyl acetate 5 volumes
  • the crystalline solid which formed was collected by filtration, washed with ethyl acetate and dried under vacuum to give 1 -N-(3S,4R)- trans-(4'-fluorophenyl)-3-[3',4'-methylenedioxymethylphenoxymethyl] piperidinyl butandioic acid as the paroxetine salt.
  • N-phenyloxycarbonyl paroxetine (5.0 kg ), potassium hydroxide flake (4.5 kg ) and toluene (75.0 litres) were heated to reflux under a nitrogen atmosphere. After stirring for 4 hours at reflux the contents of the reactor were allowed to cool to room temperature. Water (50 litres) was added and the mixture stirred for 30 minutes and then allowed to settle. The lower aqueous layer was drained from the reactor and the toluene layer heated to reflux and dried in a Dean and Stark apparatus. Toluene (10 litres) was added and approximately 10 litres of the solvent was removed by distillation. The remaining solution was cooled to approximately 90-95°C and solid maleic acid (1.04 kg) was added with vigorous stirring.
  • IR ⁇ maxcm 1 ) 1608, 1512, 1376, 1298, 1234, 1181, 1143, 1106, 1033, 930, 831,
  • Example 4 Preparation of l-N-(3S,4R)-trans-(4-fluorophenyl)-3-[3,4- methylenedioxymethyloxymethyl] piperidinyl butandioic acid.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des composés représentés par la formule générale (1) ainsi que certains métaux alcalins et amine et certains de leurs sels d'addition acides convenant au traitement de troubles du système nerveux central.
EP99961195A 1998-12-11 1999-12-10 Derive paroxetinique Withdrawn EP1137646A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9827431 1998-12-11
GBGB9827431.9A GB9827431D0 (en) 1998-12-11 1998-12-11 Novel compound
PCT/GB1999/004176 WO2000035910A1 (fr) 1998-12-11 1999-12-10 Derive paroxetinique

Publications (1)

Publication Number Publication Date
EP1137646A1 true EP1137646A1 (fr) 2001-10-04

Family

ID=10844142

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99961195A Withdrawn EP1137646A1 (fr) 1998-12-11 1999-12-10 Derive paroxetinique

Country Status (5)

Country Link
EP (1) EP1137646A1 (fr)
JP (1) JP2002532494A (fr)
AU (1) AU1788800A (fr)
GB (1) GB9827431D0 (fr)
WO (1) WO2000035910A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL362660A1 (en) 2000-12-29 2004-11-02 Pfizer Limited Process for making amlodipine maleate
US6653481B2 (en) 2000-12-29 2003-11-25 Synthon Bv Process for making amlodipine
AT5874U1 (de) 2000-12-29 2003-01-27 Bioorg Bv Pharmazeutische zubereitungen enthaltend amlodipinmaleat
US7335380B2 (en) 2000-12-29 2008-02-26 Synthon Ip Inc. Amlodipine free base
MXPA03005882A (es) 2000-12-29 2005-04-19 Pfizer Ltd Derivado amida de amlodipina.
CA2433181C (fr) 2000-12-29 2005-11-22 Pfizer Limited Fumarate d'amlodipine
CA2433193C (fr) 2000-12-29 2006-01-31 Pfizer Limited Derive d'amide d'amlodipine
EP1309558A1 (fr) 2000-12-29 2003-05-14 Synthon Licensing, Ltd. Derive aspartate de l'amlodipine utilise comme antagoniste des canaux calciques
WO2002054062A2 (fr) 2000-12-29 2002-07-11 Pfizer Limited Standards de reference destines a la determination de la purete ou de la stabilite de maleate d'amlodipine et procedes correspondants
CA2433190C (fr) 2000-12-29 2005-11-15 Pfizer Limited Amlodipine hemimaleate

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8430581D0 (en) * 1984-12-04 1985-01-09 Ferrosan As Treatment
DE29724281U1 (de) * 1997-06-10 2000-08-10 Synthon Bv 4-Phenylpiperidin-Verbindungen
EP1053234A1 (fr) * 1998-02-06 2000-11-22 Smithkline Beecham Plc Sels de paroxetine
EA200001050A1 (ru) * 1998-04-09 2001-04-23 Смитклайн Бичам Плс Малеат пароксетина

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0035910A1 *

Also Published As

Publication number Publication date
WO2000035910A1 (fr) 2000-06-22
JP2002532494A (ja) 2002-10-02
GB9827431D0 (en) 1999-02-03
AU1788800A (en) 2000-07-03

Similar Documents

Publication Publication Date Title
CA2782517A1 (fr) Formes polymorphes de chlorhydrate de 1-¬4-(5-cyanoindol-3-yl)butyl|-4-(2-carbamoylbenzofuran-5-yl)piperazi ne
EP1078925A1 (fr) Composés 4-phenylpiperidine
EP0674514A1 (fr) Utilisation d'amines cycliques a substitution aryloxyalkyle comme antagonistes des canaux a calcium et nouveaux derives de piperidine phenyloxyalkyle
WO2000035910A1 (fr) Derive paroxetinique
EP1137636A1 (fr) Procede de preparation de maleate de paroxetine
CA2164296C (fr) Chimie heterocyclique
EP2072510A1 (fr) Forme cristalline d'azélastine
SK13622000A3 (sk) Kryštalická forma paroxetínu, farmaceutický prostriedok a použitie
WO2000032595A1 (fr) Processus de production de solvate acetonique d'hydrochlorure de paroxetine
US20020137938A1 (en) Novel process
WO2001014335A1 (fr) Procede de preparation d'un intermediaire de paroxetine
WO2001012623A1 (fr) Procede de preparation d'hydrochlorure de paroxetine anhydre
EP1133492A1 (fr) Procede de fabrication d'hydrochlorure de paroxetine
WO2001025201A1 (fr) Procede de preparation de produit intermediaire de paroxetine
EP1140910A1 (fr) Procede de preparation d'un acetate de paroxetine ou d'analogues de paroxetine
WO2000078752A1 (fr) Procede de production de chlorhydrate de paroxetine
US20010008940A1 (en) Novel process
WO2000039090A1 (fr) Procede de preparation d'acetate de paroxetine et de ses analogues
JP3113447B2 (ja) アミノカルボン酸誘導体、その製造方法および用途
WO2000039122A1 (fr) Procede de preparation d'un acetate de paroxetine et de ses analogues
WO2000032596A1 (fr) Sels amines de paroxetine
WO2001017966A1 (fr) Procede de preparation de 1-methyl-3-carbomethoxy-4-(4'-fluorophenyl)-piperidine
WO2001025202A1 (fr) Procede de preparation d'intermediaire de la paroxetine
EP1140912A1 (fr) Procede de preparation d'un sel d'acetate de paroxetine ou d'analogues de paroxetine
CZ20003343A3 (cs) Krystalická forma paroxetinu

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010702

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

17Q First examination report despatched

Effective date: 20020111

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20020522